Form 10-K for the fiscal year ended December 31, 2021
We note your disclosure that except for activities you perform in connection with your collaborations with Vertex and ViaCyte, as well as in connection with the Bayer Transaction, you do not track research and development costs on a program-by-program basis.Rest of the question
Please provide us with proposed disclosure to be included in future periodic reports which separately quantifies your research and development expense related to ViaCyte and in connection with the Bayer Transaction. For the remaining expenses, please disclose by disease area or stage of development (i.e. pre-clinical and clinical). If this break out is not possible, provide disclosure of total research and development expenses incurred during each period presented by nature which should reconcile to total research and development expense on the Statements of Operations.
No. 1. The Company respectfully acknowledges the Staff’s comment and advises the Staff that with respect to research and development expenses attributable to its collaborations with Vertex, ViaCyte and the BayerRead in the reply
Transaction (as such terms are defined in the Company’s filings with the Commission), the Company has disclosed such expenses that in its judgement are material to the understanding of its results of operations.Rest of the answer
Specifically, with respect to
Vertex, beginning with the Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2022 that was filed with the Commission on May 9, 2022, the Company has separately disclosed collaboration costs under its collaboration with Vertex as, “Collaboration Expense, Net”, on its own line under “Operating Expenses” on pages 21-22 and described in more detail on page 20.
Management has determined that expenses attributable to the Company’s other collaborations and partnerships, including with ViaCyte and in connection with the Bayer Transaction, are not material to an understanding of its results of operations at this time and therefore do not warrant separate disclosure. If, and to the extent, management determines research and development expenses in connection with any of its collaborations or partnerships are material to the understanding of the
Company’s results of operations, such expenses will be separately disclosed in future periodic reports.
In addition, the Company respectfully advises the Staff that it classifies its research and development expenses as either external or internal. The Company’s external research and development expenses support its various preclinical and clinical programs, and as such the Company does not break down external research and development expenses further. The Company’s internal research and development expenses consist of payroll and benefits expenses, facilities expense, and other indirect research and development expenses incurred in support of overall research and development activities and as such are not allocated to a specific development stage or therapeutic area.
Page
Further, the Company respectfully advises the Staff that, in addition to its existing tabular disclosure regarding the Company’s results of operations (which is inclusive of research and development expenses) and discussion of research and development expenses across periods, the Company intends to include the following disclosure in its future periodic reports to provide additional detail about its’ external and internal research and development expenses:
Expenses
Research and development expenses were $[ ] for the [period] ended [date], compared to $[ ] for the [period] ended [date]. The following table summarizes our research and development expenses for the [period] ended [date] and [date], together with the changes in those items in dollars (in thousands):
[Year][X-months] ended [DATE]
[Year]
Change
External research and development expenses
$
[
]
Employee related expenses
Facility expenses
Stock-based compensation expenses
Other expenses
Sublicense and license fees
Total
The [increase][decrease] of approximately $[ ] was primarily attributable to the following:
•
$[ ] of [increased][decreased] external research and development costs, primarily related to [ ];
$[ ] of [increased][decreased] employee related expenses, primarily related to
[ ];
$[ ] of [increased][decreased] facility-related expenses, primarily related to
$[ ] of [increased][decreased] stock-based compensation expenses, primarily related to
$[ ] of [increased][decreased] other expenses, primarily related to
[ ]; and
$[ ] of [increased][decreased] sublicenses and license fees, primarily related to
[ ].
First report after the company's reply of Jun 23, 2022: 10-Q filed Aug 8, 2022 ↗, against the 10-Q filed May 9, 2022 ↗.
Tickdelta does not hold the text of both reports, so they are not compared here.
Also in this review: closing letter, 2022-07-13